On Tuesday, Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.

VERDI Solutions, headquartered in Vienna, Austria, is developing personalized cancer treatment by integrating artificial intelligence (AI) and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines.

VERDI's cloud-computing platform enables the rapid development of personalized peptide vaccines tailored to individual cancer patients. Additionally, the company is developing off-the-shelf cancer vaccines paired with companion diagnostics.

Also Read: EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

In some European countries, oncologists may administer personalized cancer vaccines under Individueller Heilversuch (Individual Healing Attempt), which allows physicians to prescribe individualized treatments.

Unlike clinical trials, where only a limited number of eligible patients can be enrolled, Heilversuch offers treatment options for any cancer patient, potentially providing valuable insights into the efficacy and safety of personalized vaccines in real-world settings.

VERDI has developed personalized vaccines using sequence data from the primary tumors for three patients with bone metastases, which their oncologists administered under Heilversuch.

Under the letter of intent, VERDI has granted Anixa a six-month exclusive right to negotiate a transaction for the research, development, and commercialization of VERDI's cancer vaccines.

While VERDI continues to develop personalized vaccines for individual treatment attempts in Europe, VERDI and Anixa plan to initiate clinical trials in the United States.

On Monday,  the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a key patent application covering Anixa Biosciences' ovarian cancer vaccine technology.

The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment.

Price Action: ANIX stock closed at $3.20 on Monday.

Read Next:

• Analyst Initiates Coverage On ‘Undervalued' Summit Therapeutics

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.